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The availability of Xpert MTB/RIF offers the potential for rapid, 
accurate diagnosis of tuberculosis (TB).1 This has generated new 
hope in resource-constrained countries with high burdens of TB/HIV 
co-infection. It has also created a dilemma: how to manage patients 
with TB symptoms who receive a negative Xpert test result for their 
initial sputum sample. HIV co-infection often results in a low TB 
bacillary load in sputum, so the sensitivity of acid-fast bacilli smear 
microscopy (AFB) is only 38 - 47% in this population.2,3 
The World Health Organization (WHO) has recommended Xpert 
as the first-line diagnostic for adult patients with possible HIV/ TB 
co-infection.4 However, the sensitivity of a single Xpert test in 
AFB-negative patients, estimated at 62 - 79%, is also inadequate, 
though substantially better than for AFB.1,5,6 Meanwhile, TB has 
relatively rapid disease progression and high mortality rates in HIV-
infected subjects.7 The high proportion of these patients who are left 
undiagnosed after a single Xpert test is therefore a concern. 
In SA, the TB/HIV co-infection rate is estimated at 60%.8 In 
March 2011, the country announced its intention of replacing smear 
microscopy with Xpert for TB diagnosis. In 2011, the National Health 
Laboratory Service (NHLS) completed over 5 million sputum smear 
microscopy tests, including samples for TB treatment monitoring 
and diagnosis. This represents an approximate 10% increase over the 
previous year, due in part to national campaigns for intensified TB and 
HIV case finding. Assuming that this rate of annual growth can be 
maintained then in 2014, once Xpert has been fully rolled out across 
SA, 2.5 million persons with TB symptoms will be tested with it.
According to SA’s current diagnostic algorithm for pulmonary TB 
(PTB), HIV-infected patients with possible TB whose first Xpert test 
was negative have to return to the clinic and provide a second sputum 
sample to be sent for culture. The patient is also asked to undergo 
a clinical examination and chest X-ray and started on presumptive 
antibiotic therapy.9 A model developed to estimate the cost of 
implementing Xpert MTB/RIF in South Africa highlights the cost of 
this diagnostic challenge.10 
Assuming both a stable TB epidemic and a stable HIV epidemic, 
in 2014 approximately 1.4 million HIV-infected persons, comprising 
53% of all patients with possible TB, will test Xpert-negative but 
possibly still have TB. Although the current algorithm provides 
‘gold standard’ for diagnostic results, it is expensive. The 53% of 
patients with possible TB who will require culture after Xpert 
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than X/C. The cost per TB patient initiated on treatment under X/X is R2 682, which is 12% less than under X/C (R3 046).
Conclusions. Modifying the diagnostic algorithm from X/C to X/X could provide rapid results, simplify diagnostic processes, improve 
HIV/TB treatment outcomes, and generate cost savings.
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will account for 60% of the total cost of diagnosing PTB in South 
Africa.9 Approximately 3% of these Xpert-negative patients will 
have a positive culture result, accounting for only 10% of all TB 
cases diagnosed in South Africa. A very large share of resources will 
therefore be spent to identify just 10% of TB patients. Culture results, 
moreover, are only available 2 - 6 weeks after sputum collection. With 
limited laboratory capacity, delays in sample transport, and weak 
information and patient follow-up systems, results may only reach 
patients months later, if at all. This delay contributes to a high rate of 
patient loss to follow-up after initial clinic presentation.1
Studies indicate that Xpert sensitivity increases with additional sputum 
samples tested.6,11 Because of the relatively high cost of Xpert MTB/RIF 
cartridges, however, algorithms using multiple Xpert tests have been 
confined to research. One modelling effort concluded that, compared 
with the use of two cultures or a single Xpert, an algorithm containing 
two Xpert tests was cost-effective in a pre-antiretroviral therapy (ART) 
population, regardless of the presence of TB symptoms.12 
However, the differences between the modelled population and 
algorithms and the current standard of care in SA make this finding 
difficult to apply to the national diagnostic algorithm. 
We set out to inform debates about the optimal use of Xpert in 
diagnosis of PTB in a context of high TB/HIV co-infection and 
low rates of AFB-positivity among patients with possible TB. To do 
this, we estimated the impact and costs of an alternative diagnostic 
algorithm in which culture, X-ray and antibiotic therapy (current 
Xpert diagnostic algorithm, abbreviated as Xpert/culture, or X/C) 
are replaced by a second Xpert test using a second sputum sample 
(proposed Xpert algorithm, abbreviated as Xpert/Xpert, or X/X). 
We used a national-level model projecting the costs of reaching full 
coverage with Xpert technology, developed by our team for the South 
African Department of Health in 2011.10 
Methods
The National TB Cost Model captures the TB diagnostic process, 
starting with patients with possible TB, continuing to TB cases, 
and ending with completion of TB treatment.10 This population-
level decision model estimates numbers of TB cases and costs for 
the financial years 2011 to 2016, with full-scale Xpert roll-out and 
implementation achieved in 2014. All results reported here are 
extrapolations for 2014. The development of the National TB Cost 
Model was approved by the Human Research Ethics Committee of 
the University of the Witwatersrand and the Institutional Review 
Board of Boston University Medical Campus.
Scenarios and algorithms
The model follows quarterly cohorts of TB patients with possible 
TB through up to three diagnostic visits under two scenarios. The 
X/C scenario represents the current Xpert diagnostic algorithm for 
patients with possible TB/HIV co-infection. Under X/C, an initial 
negative Xpert is followed by a second visit comprising a TB culture 
using a second sputum sample, a clinical examination, a chest X-ray, 
and antibiotic therapy. The X/X scenario is the alternative diagnostic 
algorithm, in which the visit that follows an initial negative Xpert is 
comprised of a second Xpert using a second sputum sample, and omits 
Fig. 1. Xpert/culture (X/C) and Xpert/Xpert (X/X) pulmonary TB diagnostic algorithms (adults >15 years). MTB = Mycobacterium tuberculosis; PTB = 
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the other procedures (culture, examination, X-ray, and antibiotics). 
Under both scenarios, patients are counted as diagnosed even if they 
fail to return to receive their results, though such patients would not be 
assumed to initiate treatment. As per South African TB guidelines, patients 
with a positive AFB, culture, or Xpert result are counted as having TB, 
meaning that the effective specificity of these tests is assumed to be 100%. 
Fig 1 illustrates the diagnostic algorithms used in this analysis.
The number of patients to be evaluated for TB (i.e. patients 
with a positive TB symptom screen) was calculated using data 
on the general population aged 15 years and above from the 
Actuarial Society of South Africa AIDS Model,13 as well as an 
assumption of prevalence of TB symptoms of 5.5% based on the 
Provincial Quarterly TB Reports.14 Based on analysis of the NHLS 
2010 database, 20% of patients evaluated in 2011 were found to 
be TB positive. This rate decreases over time as a function of case 
finding initiatives (increased numbers of patients evaluated for 
TB), allowing us to model a stable epidemic. 
Diagnostic parameters 
AFB, culture, and HIV positivity rates for the model were estimated 
from a random sample of all patients entered into the national-level 
National Health Laboratory Service (NHLS) 2010 TB specimen 
database, and a random sample of all patients entered into the 
national-level 2010 Electronic TB Register. For this analysis, the 
model was updated with results of the pilot phase of national Xpert 
implementation through to the end of February 2012. Table 1 lists the 
model inputs and assumptions and their sources.
Cost parameters 
Cost parameters are presented in Table 2. We calculated the cost of 
TB diagnosis from the government perspective, including the cost 
of outpatient visits, antibiotics, and laboratory and radiological tests. 
We used expert opinion and public-sector salary data to estimate 
the duration and cost of clinic visits, and 2011 NHLS charges for all 
laboratory costs except the Xpert test. 
The new NHLS charge for the Xpert test, including the local price 
of cartridge procurement, operator time, sputum transport, quality 
assurance, and laboratory operating overheads, was set at R166 after 
the announcement of a global price reduction for Xpert MTB/RIF 
cartridges to US$9.98.15 
No costs for MDR-TB treatment have been published for South Africa. 
We therefore used WHO CHOICE unit costs for inpatient days at public-
sector tertiary-level hospitals, as well as outpatient visits at secondary-
level hospitals,16 to estimate costs for drug-resistant TB treatment 
according to new South African policy guidelines issued in 2011.9 WHO 
CHOICE costs for outpatient visits at health facilities with no beds were 
used for drug-sensitive TB treatment. Current estimates for patient loss-
to-follow-up and death during TB treatment8,9,17 were incorporated, and 
2011 public-sector drug costs were applied to standardised regimens. 
Costs are reported in ZAR at 2011 exchange rates (US$1 = ZAR 7.23),18 
undiscounted and excluding value-added tax. 
Sensitivity analysis 
In sensitivity analysis, we systematically varied eight central parameters: 
• +/-25% in the cost of the Xpert test 
• +/-25% in the proportion of patients with possible TB who have 
known HIV infection5 
• +/-50% in the proportion of patients lost at each visit 
• +/-20% in Xpert sensitivity for smear-negative TB6 
• +/-50% in the proportion of TB which is smear positive11 
• +/-50% in the TB positivity rate 
• +/-50% access to LPA testing 
• +/-50% proportion testing rifampicin resistant. 
The per cent variation for each parameter was based on its 
variation in published literature.
Results
At full scale-up in 2014, the current diagnostic algorithm, X/C, 
will cost an estimated R1 095 million (Table 3). The alternative 
algorithm, X/X, will cost R969 million. X/X thus generates a total 




Coverage of Xpert MTB/RIF 
(sub- districts)
100% NHLS 2012
Coverage of line probe assay for 
RIF+INH detection (provincial)
62% NHLS TB 
database
Coverage of fluorescent smear 
microscopy (sub-districts)
100% NHLS TB 
database
Coverage of liquid culture, 
including DST (provincial)
100% NHLS TB 
database
Coverage of chest X-ray 100% Assumption
TB incidence, per 100 000 
population
981 WHO8
Annual growth in number of 
patients to be evaluated for TB
10% SANAC21
Number of patients to be 
evaluated for TB
2 573 504 Meyer-Rath et al.10
Proportion of patients with 
possible TB known to be HIV+ 
56% ETR 2010
Proportion of patients with 
possible TB, HIV status unknown 
(managed as if HIV+)
6% ETR 2010
Proportion sputum smear+ 
(2 sputa)
7% NHLS TB 
database
Proportion culture+ if smear- 9% NHLS TB 
database
RIF + INH resistance (MDR-TB) 3% Weyer et al.22
Xpert MTB sensitivity, smear+ 100% Boehme et al.1
Xpert MTB sensitivity, smear- 79% Boehme et al.1
Xpert MTB/RIF failure rate 2% Meyer-Rath et al.10
RIF resistance 3% Weyer et al.22
Xpert RIF sensitivity 90% Boehme et al.1
Proportion lost to follow-up at 
visits 1, 2, 3
13%, 26%, 
39%
Boehme et al.1, 
assumption
Proportion lost to follow-up 
or dead, 1st-line treatment
14% WHO8
Proportion lost to follow-up 
or dead, MDR-TB treatment
30% DoH9
Proportion of patients with 
MDR-TB who develop XDR-TB
10% WHO8
Proportion of patients who die 
during XDR-TB treatment
36% Dheda et al.17
MTB = Mycobacterium tuberculosis; RIF = rifampicin (resistance); INH = isoniazid 
(resistance); DST = anti-TB drug-sensitivity testing; MDR-TB = multidrug-resistant TB; 
XDR-TB = extensively drug-resistant TB; NHLS = National Health Laboratory Service;  
ETR = Electronic TB Register; SANAC = South African National AIDS Council; 
DoH = South African Department of Health; WHO = World Health Organization.
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annual cost saving of R126 million (US$17.4 million), or 11% of 
total cost of diagnosis. 
The cost per TB case initiated on treatment among HIV-positive, first 
Xpert-negative patients is R3 046 under X/C, compared with R2 682 
under X/X (12% less). Cost savings from an X/X algorithm could be 
realised immediately, although their total value would be proportional to 
the extent of the roll-out of Xpert in 2012 and 2013 (results not shown). 
Under the X/X algorithm, 2% fewer TB cases and 2% fewer MDR-
TB cases are diagnosed because Xpert is less sensitive than culture. 
However, because loss to follow-up during the diagnostic process is 
expected to be substantially lower than in X/C, 1% more TB cases and 
1% more MDR-TB cases are initiated on appropriate TB treatment 
under the X/X algorithm. This in turn would raise overall treatment 
costs by 1%. Therefore, the total (diagnosis and treatment) annual 





Xpert MTB/RIF cartridge R110.00 Cepheid, South Africa 2012
Xpert MTB/RIF test (including cartridge) R166.20 NHLS charges 2012
AFB microscopy (2 sputa) R44.54 NHLS charges 2011
Liquid culture, no growth R88.71 NHLS charges 2011
Liquid culture, growth (including LPA if available) R261.00 NHLS charges 2011
RIF, INH drug sensitivity testing (if not done by LPA) R304.09 NHLS charges 2011
Chest X-ray R110.00 2011 public sector prices
Empirical antibiotics R11.00 2011 public sector prices
Nurse visit R71.14 Department of Public Service and Administration, 2011
Doctor visit R129.63 Department of Public Service and Administration, 2011
Treatment costs Drug costs: 2011 public sector prices
Outpatient care: WHO CHOICE (South Africa), health 
facility no beds; monthly outpatient secondary-level 
hospital for DR-TB
Inpatient care: WHO CHOICE tertiary-level hospital16
Drug-sensitive TB R2 768.00
RIF mono-resistant TB R17 329.00
INH mono-resistant TB R4 931.00
MDR-TB R55 525.00
XDR-TB R205 910.00
MTB = Mycobacterium tuberculosis; RIF = rifampicin (resistance); INH = isoniazid (resistance); AFB = acid-fast bacilli smear microscopy; LPA = line probe assay for anti-TB drug 
resistance testing; MDR-TB = multidrug-resistant TB; XDR-TB = extensively drug-resistant TB; DR-TB = drug-resistant TB; NHLS = National Health Laboratory Service; WHO CHOICE 
= choosing cost-effective interventions.
Table 3. 2014 results of Xpert/culture v. Xpert/Xpert pulmonary TB diagnostic algorithm (2011 ZAR)
Base case scenario X/C X/X
Incremental change 
of X/X over X/C %
Number of TB cases diagnosed, N 426 558 418 079 -8 479 -2
Number of MDR-TB cases diagnosed, N 11 033 10 861 -172 -2
Number of TB cases initiated on treatment, N 359 274 361 136 +1 862 +1
Number of MDR-TB cases initiated on treatment, N 9 341 9 397 +56 +1
Total annual cost of PTB diagnosis, ZAR R1 095 million R969 million -R126 million -11
Cost per patient evaluated for TB, ZAR R427 R376 -R51 -12
Cost per case diagnosed, ZAR R2 566 R2 317 -R249 -10
Cost per case initiated on treatment, ZAR R3 046 R2 682 -R364 -12
Patients with TB diagnosis within 1 week, % 87% 89% +2% +2
Total annual cost PTB diagnosis and treatment, ZAR R2 312 million R2 194 million -R118 million -6
Cost per TB patient treated, ZAR R6 435 R6 076 -R359 -5
X/C = diagnostic algorithm using culture for HIV+/Xpert- patients evaluated for TB; X/X = diagnostic algorithm using Xpert for HIV+/Xpert- patients evaluated for TB; PTB = pulmonary TB; 
MDR-TB = multidrug-resistant TB; XDR-TB = extensively drug-resistant TB.
RESEARCH
105  February 2013, Vol. 103, No. 2  SAMJ
cost of SA’s PTB programme would be R2 194 million under X/X, 
which is 6% (R118 million) less than the R2 312 million under X/C. 
Sensitivity analysis
Of the parameters tested in sensitivity analysis, the incremental cost 
of the X/X algorithm was sensitive only to variations in the cost of an 
Xpert test. However, in August 2012, a public-private partnership with 
major international donors announced a buy-down of Xpert MTB/RIF 
cartridges so that the price of US$9.98 will not increase before 2020.15 
Systematic variation in this and all other parameters still led to 
annual cost savings from using an X/X diagnostic algorithm (Fig. 2). 
The number of cases of TB diagnosed and treated under each 
algorithm was sensitive to variation in the sensitivity of Xpert in AFB-
negative TB. The assumed Xpert sensitivity of AFB-negative TB is 
79%, lower than the sensitivity of culture. Therefore in most instances 
the total number of cases diagnosed in the X/X algorithm is slightly 
lower (average -2%) than the X/C algorithm. In these same scenarios, 
however, the number of TB patients initiated on treatment under X/X 
remains slightly higher (average +1%) because of the shortened time 
to diagnosis and consequent reduction in loss of patients.
Discussion
Declining international funding for HIV and TB programmes19 makes 
it essential that available resources be used as efficiently as possible to 
achieve public health goals. Newly-available diagnostic technologies for 
TB promise vastly improved diagnosis of the disease, particularly among 
the large population of TB/HIV co-infected patients in many low- and 
middle-income countries. However, access to these technologies poses 
the challenge of identifying the most efficient ways to use them, within 
the budgetary constraints of the overall public health systems.
We used a model parameterised for SA to compare two strategies 
for diagnosing TB in HIV co-infected patients where Xpert MTB/
RIF technology is available. We found that for almost all parameter 
values considered, a diagnostic algorithm that follows an initial 
negative Xpert with a second Xpert, rather than with culture 
combined with examination, X-ray and antibiotics, reduces costs 
substantially, without meaningfully affecting the number of patients 
initiating TB treatment. 
The estimated R118 million annual saving from the X/X algorithm 
is roughly equal to the cost of providing isoniazid as prophylactic 
therapy for all HIV-infected patients who are found not to have 
active TB disease. The X/X algorithm is also likely to reduce patient-
level costs and treatment delays, directly benefiting those with TB. 
Furthermore, reducing patient loss to follow-up before treatment 
initiation may diminish the duration of exposure to active TB among 
patients’ families, co-workers and other contacts, and hence reduce 
TB transmission. The combination of budget savings and benefits to 
patients and their households argues that SA policymakers should 
seriously consider the proposed X/X strategy.
As large-scale rollout of Xpert MTB/RIF is just beginning in SA, it 
is uncertain how implementation will progress and what the results 
will be. We therefore had to make several assumptions that influence 
our results. For example, our analysis assumed that guidelines will 
be followed and tests performed correctly, but healthcare worker 
preferences and patient behaviour will certainly affect implementation 
of either algorithm. The pilot roll-out in SA indicates that laboratory 
technicians, clinicians and patients will prefer X/X’s ease of use and 
rapid results over the multiple visits, reliance on clinical interpretation 
and delayed results when using culture and clinical diagnosis.20 
While X/X is one obvious alternative diagnostic algorithm for the 
present SA situation, other diagnostic sequences and combinations 
could be considered. For example, in some countries it may be 
desirable to use Xpert as a second test after a negative sputum smear. 
The value of the additional procedures that are combined with 
culture in the X/C algorithm – examination, X-ray, and antibiotics – 
should also be explored, as they contribute substantially to the cost 
of the algorithm. 
To reduce the overall cost of TB diagnosis, strategies should be 
explored to reduce the number of Xpert-negative HIV-infected patients 
still considered TB suspects, such as presumptive antibiotic treatment. 
Further operational research into the diagnosis of extra-pulmonary 
TB, in particular the collection of specimens from extrapulmonary foci 
at primary healthcare level, could also reduce the number of Xpert-
negative patients who are symptomatic but undiagnosed. 
While these findings pertain to SA, they are applicable to other 
countries that are debating the appropriate placement of Xpert 
within their TB diagnostic algorithms, especially countries with 
high rates of TB/HIV co-infection. Once the initial investment in 
Xpert technology has been made, analysis suggests that performing 
a second Xpert test instead of a culture will conserve scarce clinical 
Fig. 2. Tornado diagram of difference of total annual diagnostic cost (millions ZAR, 2011) between Xpert/culture and Xpert/Xpert as a result of percentage 
change in assumed parameter values. R0 set at base case difference of –R118 million.
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and laboratory skills, reduce costs, relieve patients of having to make 
multiple clinic visits, and accelerate availability of results. 
Countries that do not replace smear microscopy with Xpert across 
all laboratories, but rather establish Xpert capacity in a few central 
ones, may still find that our proposed algorithm has cost advantages 
for diagnosing TB in patients who are initially AFB-negative, though 
this would require further analysis using different model parameters.
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